Jun 2026 (Q2 FY26) — Aug 5, 2026
UroGen Pharma Q2 FY26 — ZUSDURI Revenue Surges 73% QoQ, Pipeline Advances
Read the full callUroGen Pharma (URGN) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
UroGen Pharma earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 72.5 | +199.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 0.1 | +171.3 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -14.4 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$34.15 −1.19% · −$0.41
Performance +101.5% 1Y
1Y: $16.95 on 17 Oct 2025 → $34.15. High $50.29 (19 Aug 2026), low $16.95 (17 Oct 2025).
- Previous close
- $34.56
- 52-week range
- $17 – $50.29
- One year
- +89.72%
Overview
- Symbol
- URGN
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
UroGen Pharma earnings calls (URGN)
Financials
What the filings say
Net profit, year on year: +71% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 25 | 25 | 20 | 24 | 27 | 38 | 51 | 72 |
| Operating profit | -18 | -28 | -37 | -41 | -27 | -19 | -20 | 0 |
| Operating margin | −69.6% | −112.6% | −182.3% | −171.2% | −99.7% | −50.5% | −39.8% | 0.1% |
| Other income | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Profit before tax | -24 | -35 | -43 | -49 | -34 | -27 | -28 | -9 |
| Tax rate | −0.4% | −7.6% | −0.9% | −2.1% | 3.1% | 1.0% | 16.8% | −64.5% |
| Net profit | -24 | -38 | -44 | -50 | -33 | -26 | -24 | -14 |
| EPS ($ per share) | -0.51 | -0.80 | -0.92 | -1.05 | -0.69 | — | -0.47 | -0.28 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -123 | -228 | -357 | -467 | -577 | -679 | -806 | -960 |
| Total liabilities | 13 | 22 | 26 | 111 | 225 | 244 | 295 | 306 |
| Fixed assets | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 |
| Investments | — | — | — | — | — | 56 | 111 | 49 |
| Total assets | 104 | 202 | 122 | 120 | 136 | 178 | 286 | 200 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -37 | -71 | -106 | -85 | -88 | -76 | -97 | -162 |
| Cash from investing | 35 | -146 | 93 | 4 | 1 | -1 | -21 | 62 |
| Cash from financing | 66 | 165 | 17 | 72 | 97 | 117 | 195 | 40 |
| Net cash flow | 64 | -51 | 4 | -9 | 11 | 40 | 77 | -61 |
| Capital expenditure | -1 | -0 | -1 | -1 | -0 | -0 | -0 | -0 |
| Free cash flow | -38 | -71 | -107 | -86 | -88 | -77 | -97 | -163 |
Insider filings
32 filings between Nov 19, 2025 and Oct 8, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$4.77M
15 sales by 3 insiders
27% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 17
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Schoenberg Mark | — | $4.48M | Sep 8, 2026 |
| Smith Jason Drew | — | $211.9K | Sep 8, 2026 |
| Degnan Chris | — | $80.8K | Oct 8, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 8, 2026 | Degnan Chris Chief Financial Officer | Sale | 2,202 | $80.8K |
| Oct 8, 2026 | Degnan Chris Chief Financial Officer | Option exercise | 4,483 | — |
| Sep 8, 2026 | Smith Jason Drew General Counsel | Sale | 1,519 | $64.6K |
| Sep 8, 2026 | Schoenberg Mark Chief Medical Officer | Sale | 871 | $37.4K |
| Sep 7, 2026 | Smith Jason Drew General Counsel | Option exercise | 3,334 | — |
| Sep 7, 2026 | Schoenberg Mark Chief Medical Officer | Option exercise | 1,667 | — |
| Aug 26, 2026 | Robinson James A. Jr. Director | Option exercise | 2,000 | — |
| Aug 20, 2026 | Schoenberg Mark Chief Medical Officer | Sale | 60,677 | $2.85M |
| Jul 9, 2026 | Schoenberg Mark Chief Medical Officer | Sale 10b5-1 plan | 10,000 | $400.0K |
| Jun 22, 2026 | Schoenberg Mark Chief Medical Officer | Sale 10b5-1 plan | 10,000 | $350.1K |
| Jun 8, 2026 | Schoenberg Mark Chief Medical Officer | Sale | 5,222 | $142.6K |
| Jun 8, 2026 | Schoenberg Mark Chief Medical Officer | Option exercise | 10,000 | — |
| May 26, 2026 | Robinson James A. Jr. Director | Option exercise | 2,000 | — |
| May 8, 2026 | Schoenberg Mark Chief Medical Officer | Sale 10b5-1 plan | 10,000 | $300.0K |
| Feb 3, 2026 | Smith Jason Drew General Counsel | Sale | 3,217 | $63.3K |
| Feb 3, 2026 | Smith Jason Drew General Counsel | Sale | 2,654 | $52.3K |
| Feb 3, 2026 | Smith Jason Drew General Counsel | Sale | 1,608 | $31.7K |
| Feb 3, 2026 | Schoenberg Mark Chief Medical Officer | Sale | 1,843 | $36.3K |
| Feb 3, 2026 | Schoenberg Mark Chief Medical Officer | Sale | 3,686 | $72.6K |
| Feb 3, 2026 | Schoenberg Mark Chief Medical Officer | Sale | 1,844 | $36.3K |
| Jan 31, 2026 | Smith Jason Drew General Counsel | Option exercise | 5,500 | — |
| Jan 31, 2026 | Smith Jason Drew General Counsel | Option exercise | 6,667 | — |
| Jan 31, 2026 | Smith Jason Drew General Counsel | Option exercise | 3,333 | — |
| Jan 31, 2026 | Schoenberg Mark Chief Medical Officer | Option exercise | 3,334 | — |
| Jan 31, 2026 | Schoenberg Mark Chief Medical Officer | Option exercise | 6,666 | — |
| Jan 31, 2026 | Schoenberg Mark Chief Medical Officer | Option exercise | 3,333 | — |
| Nov 26, 2025 | Robinson James A. Jr. Director | Option exercise | 2,000 | — |
| Nov 26, 2025 | Holden Stuart Director | Option exercise | 2,000 | — |
| Nov 26, 2025 | Wildman Daniel George Director | Option exercise | 2,000 | — |
| Nov 26, 2025 | WEN LEANA Director | Option exercise | 2,000 | — |
| Nov 26, 2025 | BUTITTA CYNTHIA M Director | Option exercise | 2,000 | — |
| Nov 19, 2025 | Schoenberg Mark Chief Medical Officer | Sale 10b5-1 plan | 10,000 | $250.0K |
| Oct 8, 2025 | Degnan Chris Chief Financial Officer | Sale | 2,203 | $37.1K |
| Oct 8, 2025 | Degnan Chris Chief Financial Officer | Option exercise | 4,483 | — |
| Sep 8, 2025 | Schoenberg Mark Chief Medical Officer | Sale | 871 | $16.6K |
| Sep 8, 2025 | Smith Jason Drew General Counsel | Sale | 1,520 | $29.0K |
| Sep 7, 2025 | Smith Jason Drew General Counsel | Option exercise | 3,333 | — |
| Sep 7, 2025 | Schoenberg Mark Chief Medical Officer | Option exercise | 1,667 | — |
| Aug 11, 2025 | Schoenberg Mark Chief Medical Officer | Sale | 10,000 | $176.9K |
| Jul 28, 2025 | Smith Jason Drew General Counsel | Sale | 7,522 | $144.0K |
| Jul 28, 2025 | Schoenberg Mark Chief Medical Officer | Sale | 5,149 | $98.6K |
| Jul 28, 2025 | Smith Jason Drew General Counsel | Option exercise | 16,500 | — |
| Jul 28, 2025 | Schoenberg Mark Chief Medical Officer | Option exercise | 10,000 | — |
| Jun 9, 2025 | Schoenberg Mark Chief Medical Officer | Sale | 5,162 | $38.0K |
| Jun 8, 2025 | Schoenberg Mark Chief Medical Officer | Option exercise | 10,000 | — |
| Feb 26, 2025 | Robinson James A. Jr. Director | Option exercise | 2,000 | — |
| Jan 31, 2025 | Schoenberg Mark Chief Medical Officer | Sale | 759 | $8.5K |
| Jan 31, 2025 | Schoenberg Mark Chief Medical Officer | Option exercise | 3,333 | — |
| Jan 31, 2025 | Schoenberg Mark Chief Medical Officer | Sale | 1,896 | $21.1K |
| Jan 31, 2025 | Schoenberg Mark Chief Medical Officer | Option exercise | 3,333 | — |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for UroGen Pharma Ltd.
Free account. Everything above stays public.
Write why you follow UroGen Pharma Ltd. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading